跳轉至內容
Merck
  • Pharmacokinetics of loxoprofen and its active metabolite after dermal application of loxoprofen gel to rats.

Pharmacokinetics of loxoprofen and its active metabolite after dermal application of loxoprofen gel to rats.

Die Pharmazie (2015-05-23)
R Sawamura, M Kazui, A Kurihara, T Izumi
摘要

This study was conducted to evaluate the pharmacokinetics of loxoprofen (LX) and its active metabolite (trans-OH form) after a single dermal application of LX gel (LX-G) to rats. In the skin at the treated site, generation of the trans-OH form was detected and both LX and the trans-OH form remained at high concentrations for 24 h after dermal application. Furthermore, both LX and the trans-OH form also remained in the skeletal muscle over 24 h after the single dermal application, while they eliminated rapidly after the single oral administration. The area under the curve up to the last measurable point (AUC(0-t)) for plasma concentrations of LX or the trans-OH form after dermal application of LX-G was less than 11% of that after oral administration of LX. In addition, C(max) and AUC(0-t) increased in a saturable manner while increasing the dose. Overall, these results demonstrated that the trans-OH form was generated at the treated site with the process of dermal absorption of LX and it remained at the target site for a long period with low systemic exposure compared to oral administration.

材料
產品編號
品牌
產品描述

Supelco
羟苯丙酯, Pharmaceutical Secondary Standard; Certified Reference Material
USP
4-羟基苯甲酸丙酯, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
苯巴比妥米那
Sigma-Aldrich
4-羟基苯甲酸丙酯, ≥99%
Supelco
苯巴比妥标准液 溶液, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
4-羟基苯甲酸丙酯, BioXtra
对羟基苯甲酸丙酯, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
4-羟基苯甲酸丙酯, tested according to Ph. Eur.